GILD · Gilead Sciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 51%
- Last earnings
- Oct 29, 2026
- Latest filing
- 10-Q · Oct 30
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Gilead Sciences targets 80% of 200 authorized treatment centers activating within six months, 90% payer reimbursement within the first year and brand leadership within 18 months for AnitaCell. The earliest second-line filing is 2027.
Gilead reported a nine-month net loss of $6.0 billion, driven by $11.3 billion in acquired IPR&D from acquisitions including Arcellx, Tubulis and Ouro Medicines.
Gilead's base business grew 16% year-over-year to $8.2 billion in the third quarter, and full-year base business sales guidance was raised to between $30.7 and $31 billion. CMS set Biktarvi pricing at $2,600 per 30-day supply, a net impact of approximately $1.5 billion on Biktarvi revenue expected in 2028.
Gilead Sciences reported third-quarter 2026 product sales of $8.3 billion, up 13%, and raised full-year product sales guidance to $31,000-$31,300 million. Full-year GAAP diluted loss per share is now $(4.40)-$(4.05), while non-GAAP diluted loss per share is $(1.20)-$(0.85).
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 29, 2026TL;DR. Gilead delivered 16% base-business growth, strong HIV, prevention, Trodelvy and Livdelzi results, and raised full-year sales guidance. Principal headwinds are an expected $1.5 billion Biktarvy revenue impact in 2028, declining cell therapy and Veklury sales, higher expenses and acquisition-driven loss guidance.
- + Base business sales increased 16% year-over-year to $8.2 billion, representing the strongest growth in more than a decade.
- + HIV sales increased 18% to $6.2 billion, driven by higher realized price, prevention demand and favorable inventory dynamics.
- + HIV prevention sales nearly doubled year-over-year.
- + Trodelvy sales increased 42% to $506 million on strong demand.
- + Livdelzi sales increased 93% year-over-year and 21% sequentially to $203 million on increased U.S. and European demand.
- + Gilead raised full-year base business sales guidance to $30.7 billion-$31 billion.
- − Gilead expects an approximately $1.5 billion net reduction to Biktarvy revenue in 2028 from Medicare pricing and spillover effects.
- − Cell therapy sales decreased 18% to $355 million because of ongoing competitive headwinds.
- − Veklury sales decreased 69% to $86 million because of lower COVID-19 hospitalization rates.
- − GAAP diluted EPS declined to $1.94 from $2.43.
- − Full-year non-GAAP diluted loss per share guidance worsened to $1.20-$0.85 from $0.65-$0.30 due to acquisition-related IPR&D charges.
- − SG&A expenses increased to $1.6 billion on a GAAP basis and $1.5 billion on a non-GAAP basis, reflecting promotional, acquisition-integration, legal and employee-related costs.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow non-GAAP | $5.86B | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GILD
this stock
Gilead Sciences, Inc.
|
$206.43B | +35.6% | +10.0% | — | 1.7% |
|
LLY
ELI LILLY & Co
|
$1.27T | +25.3% | +44.7% | 43.7 | 0.8% |
|
JNJ
Johnson & Johnson
|
$651.11B | +30.7% | +6.0% | 41.1 | 0.7% |
|
ABBV
AbbVie Inc.
|
$505.89B | +25.3% | +8.6% | 49.3 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$329.65B | +27.0% | +1.3% | 137.9 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GILD | -1.0% | +6.7% | +30.5% | -2.5% | +35.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +7.6% | +15.9% | +39.6% | +6.2% | +34.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.